Submitted by John Kremer, Chairperson of the 2015 Continuing Education (CE) course PM09.
Cardiovascular safety liabilities continue to be a major cause of drug attrition in late-stage clinical trials and post-market approval. Preclinical studies are increasingly incorporating more rigorous cardiovascular evaluations to better understand drug-related changes in functional and toxicological endpoints. This Society of Toxicology (SOT) 2015 Annual Meeting Continuing Education (CE) course was designed for toxicologists who are looking to expand their knowledge on how to design and interpret these functional cardiovascular data (e.g., heart rate, blood pressure, electrocardiogram) along with traditional endpoints (e.g., pathology). The four presentations are:
- Study Design Considerations to Improve Cardiovascular Safety Assessment, John J. Kremer, Covance Laboratories Inc., Madison, Wisconsin
- Hemodynamic Data: Toward Maximal Information Extraction, Bari Olivier, Michigan State University, East Lansing, Michigan
- Pathologist Viewpoint on Mapping Physiological Data to Other Indices of Toxicity Including Histopathology, Wendy Halpern, Genentech, Inc., South San Francisco, California
- Doxorubicin in NHPs: A Case Study in Using Multiple Parameters to Assess CV Function as Part of a Toxicology Study, Michael Engwall, Amgen, Thousand Oaks, California
By attending this CE course, you should better understand the considerations and strategies in integrating cardiovascular endpoints in toxicology studies as well as real-world case-studies for interpretation of these data for drug safety assessment.
Visit the PM09 CE course website for full details, including speaker biographies!
We hope to see you in San Diego at the 2015 SOT Annual Meeting.